Healthy Clinical Trial
— GPGHOfficial title:
Great Posture, Great Health - A Community-Based Postural Intervention for Improving Holistic Health
| Verified date | April 2024 |
| Source | Mayo Clinic |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to examine the effect of a posture intervention on specific areas of daily function and health: physical, psychological, cognitive, social, and environmental characteristics.
| Status | Completed |
| Enrollment | 114 |
| Est. completion date | March 19, 2024 |
| Est. primary completion date | March 19, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 12 Years and older |
| Eligibility | Inclusion Criteria: - Participants must be physically capable (defined as easy to moderate physical activities daily at least 60 minutes). - Participants also must have a normal (18.5-24.9kg/m2) or overweight BMI (25-29.9kg/m2). - Participants must be able to speak, listen, read, and understand sentences written in English. Exclusion Criteria: - More than two risk factors for coronary artery disease (high blood pressure, high blood cholesterol level (LDL), family history (a close relative with heart disease), diabetes mellitus, chronic kidney disease - History of falls, osteoporosis, osteoarthritis, or orthopedic or neurological conditions (i.e., stroke) - Medications that cause dizziness or slow movement - Smoke - Body mass to height squared ratio greater than 30kg/m2 or less than 18.4kg/m2, blood pressure greater than 140/90 mmHg, or a history of heart conditions. - Individuals with progressive cognitive, neurologic disorders, cancer treatment, chronic heart failure, or unstable medical conditions |
| Country | Name | City | State |
|---|---|---|---|
| United States | Mayo Clinic in Rochester | Rochester | Minnesota |
| Lead Sponsor | Collaborator |
|---|---|
| Mayo Clinic |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Thigh Strength | Isometric measurement (Newtons) of quadriceps and hamstrings musculature | 12-week differences (Pre- and Post-intervention measures) | |
| Primary | Posture | Posture will be measured via the Posture Screen Mobile app. Displacement (mm) | 12-week differences (Pre- and Post-intervention measures) | |
| Primary | Bone density | Bone densiometry will be measured via quantitative ultrasound (Achilles EXPII, GE). T-score. | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | PROMIS - Physical Activity | Patient Reported Outcomes from a computerized adaptive test (T-score; normative score is 1.0; higher score equates to a better outcome) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | PROMIS - Physical Function | Patient Reported Outcomes from a computerized adaptive test (T-score; normative score is 1.0; higher score equates to a better outcome) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | PROMIS - Pain Interference | Patient Reported Outcomes from a computerized adaptive test (T-score; normative score is 1.0; higher score equates to a better outcome) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | Mindful Attention Awareness Scale (MAAS) | Patient Reported Outcomes (Mean score range: 1-6; higher score equates to increased mindfulness) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | Perceived Stress Scale (PSS-10) | Patient Reported Outcomes (Score range: 0-40; higher score equates to increased stress) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | Generalized Anxiety Disorder (GAD7) | Patient Reported Outcomes (Score range: 0-21; higher score equates to increased anxiety) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | Patient Health Questionnaire Depression Scale (PHQ) | Patient Reported Outcomes (Score range: 0-27; score of 10 or greater is considered major depression, 20 or more is severe major depression.) | 12-week differences (Pre- and Post-intervention measures) | |
| Secondary | Sex | Demographic co-variate. (M/F) | Through study completion, an average of 1 year | |
| Secondary | Age | Demographic co-variate (years) | Through study completion, an average of 1 year | |
| Secondary | BMI | Demographic co-variate (BMI index; kg/m^2) | 12-week differences (Pre- and Post-intervention measures) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |